GLP-1 Receptor Agonist in Non-obese Patients with Type-2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction

•For patients with type 2 diabetes and heart failure with preserved ejection fraction, GLP-1 receptor agonist (GLP-1RA) medications may improve various heart and kidney-related outcomes even for those without obesity.•GLP-1RAs could provide incremental benefits to patients already taking other diabetes and heart failure medications like SGLT2i.•Our study provides preliminary findings that should be further studied in prospective clinical trials. Glucagon like peptide-1 receptor agonists (GLP-1RA) promote weight loss and improve heart failure-related symptoms, quality of life, and functional capacity in patients with obesity and heart failure with preserved ejection fraction (HFpEF). However, their clinical effectiveness in non-obese patients with diabetes and HFpEF is understudied. The TriNetX research network was used to identify adult patients (≥18 years) with type 2 diabetes mellitus (T2DM), Heart failure with preserved ejection fraction ((Left ventricular ejection fraction ≥45%), elevated brain natriuretic peptide (≥150pg/mL) or N-terminal pro-B-type natriuretic peptide(≥450pg/mL) and a body mass index (BMI)